Uso oftálmico de nanovehículos therapéuticos para las retinopatías con componente inflamatorio
Datos básicos
- Código Financiador:
- Año inicial:
- 2024
- Año final:
- 2026
Documentos
- No hay documentos
Participantes
Grupos de Investigación
Financiadores
INSTITUTO DE SALUD CARLOS III
Resultados del Proyecto
Evidence for cytotoxicity and mitochondrial dysfunction in human lung cells exposed to biomass burning aerosol constituents: Levoglucosan and 4-nitrocatechol
Khan, F; (...); Szmigielski, R
Article. 10.1016/j.envpol.2024.125173. 2024
Noninvasive ocular delivery of adalimumab-loaded nanostructured lipid carriers for targeted retinitis pigmentosa therapy.
Velasco S; (...); Rodrigo R
Article. 10.1016/j.biopha.2025.117962. 2025
Physiological values of phagocytic capacity in marine mammals and alterations during pathological situations.
Felipo-Benavent M; (...); O'Connor JE
Article. 10.3389/fvets.2024.1389977. 2024
The mechanistic functional landscape of retinitis pigmentosa: a machine learning-driven approach to therapeutic target discovery
Esteban-Medina, M; (...); Peña-Chilet, M
Article. 10.1186/s12967-024-04911-7. 2024